Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen

Molecular Cancer Therapeutics

Volumn 1, Issue 6, 2002, Pages 385-392

  Scott, Gary K ^a   Marden, Chloe ^a   Xu, Fan ^a   Kirk, Liana ^a   Benz, Christopher C ^a  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; DEOXYRIBONUCLEASE I; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HISTONE DEACETYLASE; HYDROXAMIC ACID; LUCIFERASE; TRICHOSTATIN A;

ARTICLE; BREAST TUMOR; CELL CULTURE; CELL SURVIVAL; DNA PROBE; DNA RESPONSIVE ELEMENT; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; NUCLEIC ACID ANALYSIS; PATHOLOGY; PROMOTER REGION; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST NEOPLASMS; BUTYRIC ACID; CELL SURVIVAL; DEOXYRIBONUCLEASE I; DNA PROBES; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; LUCIFERASES; NUCLEOTIDE MAPPING; PROMOTER REGIONS (GENETICS); RECEPTOR, ERBB-2; RESPONSE ELEMENTS; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0037726036     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Benz, C. C., and Tripathy, D. ErbB2 overexpression in breast cancer: biology and clinical translation. J. Women's Cancer, 2: 33-40, 2000.
2. Krauss, W. C., Park, J. W., Kirpotin, D. B., Hong, K., and Benz, C. C. Emerging antibody-based HER2(ErbB2/neu) therapeutics. Breast Disease, 11: 113-124, 2000.
3. Monia, B. P., Holmlund, J., and Dorr, F. A. Antisense approaches for the treatment of cancer. Cancer Investig., 18: 635-650, 2000.
4. Roh, H., Pippin, J., and Drebin, J. A. Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu. Cancer Res., 60: 560-565, 2000. (Pubitemid 30094551)
5. Suzuki, T., Anderegg, B., Ohkawa, T., Engebraaten, O., Halks-Miller, M., Holm, P. S., Curiel, D. T., Kashani-Sabet, M., and Scanlon, K. J. Adenovirus-mediated ribozyme targeting of HER2/neu inhibits in vivo growth of breast cancer cells. Gene Ther., 7: 241-248, 2000. (Pubitemid 30113773)
6. Wright, L., and Kearney, P. Current status of ribozymes as gene therapy agents for cancer. Cancer Investig., 19: 495-509, 2001. (Pubitemid 32619390)
7. Hortobagyi, G. N., Ueno, N. T., Xia, W., Zhang, S., Wolf, J. K., Putnam, J. B., Weiden, P. L., Willey, J. S., Carey, M., Branham, D. L., Payne, J. Y., Tucker, S. D., Bartholomeusz, C., Kilbourn, R. G., DeJager, J. L., Sneige, N., Katz, R. L., Anklesaria, P., Ibrahim, N. K., Murray, J. L., Theriault, R. L., Valero, V., Gershenson, D. M., Bevers, M. W., Huang, L., Lopez-Berestein, G., and Hung, M-H. Cationic liposome-mediated EIA gene transfer to human breast and ovarian cancer cells and its biologic effects: a Phase I clinical trial. J. Clin. Oncol., 19: 3422-3433, 2001. (Pubitemid 32642196)
8. Basye, J., Trent, J. O., Gao, D., and Ebbinghaus, S. W. Triplex formation by morpholino oligodeoxyribonucleotides in the HER2/neu promoter requires the pyrimidine motif. Nucleic Acids Res., 29: 4873-4880, 2001. (Pubitemid 33133559)
9. Chiang, S-Y., Bürli, R. W., Benz, C. C., Gawron, L., Scott, G. K., Dervan, P. B., and Beerman, T. A. Targeting the Ets binding site of the HER2/neu promoter with pyrrole-imidazole polyamides. J. Biol. Chem., 275: 24246-24254, 2000. (Pubitemid 30627543)
10. Scott, G. K., Chang, C. H., Erny, K. M., Xu, F., Fredericks, W. J., Rauscher, F. J., III, Thor, A. D., and Benz, C. C. Ets regulation of the erbB2 promoter. Oncogene, 19: 6490-6502, 2000. (Pubitemid 32108439)
11. Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M., and Osborne, C. K. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat., 24: 85-95, 1992. (Pubitemid 23063891)
12. Scott, G. K., Daniel, J. C., Xiong, X., Maki, R. A., Kabat, D., and Benz, C. C. Binding of an ETS-related protein within the DNase I hypersensitive site of the HER2/neu promoter in human breast cancer cells. J. Biol. Chem., 269: 19848-19858, 1994. (Pubitemid 24250899)
13. Benz, C. C., Scott, G. K., Santos, G. F., and Smith, H. S. Expression of c-myc, c-Ha-ras1, and c-ErbB2 proto-oncogenes in normal and malignant human breast epithelial cells. J. Natl. Cancer Inst., 81: 1704-1709, 1989. (Pubitemid 19275908)
14. Chang, C-H., Scott, G. K., Kuo, W-L., Xiong, X., Suzdaltseva, Y., Park, J. W., Sayre, P., Erny, K., Collins, C., Gray, J. W., and Benz, C. C. ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis. Oncogene, 14: 1617-1622, 1997. (Pubitemid 27182846)
15. Chang, C-H., Scott, G. K., Baldwin, M. A., and Benz, C. C. Exon 4-encoded acidic domain in the epithelium-restricted Ets factor ESX confers potent transactivating capacity and binds to TATA-binding protein (TBP). Oncogene, 24: 3682-3695, 1999. (Pubitemid 29338501)
16. Santos, G. F., Scott, G. K., Lee, W. M. F., Liu, E., and Benz, C. Estrogen-induced post-transcriptional modulation of c-myc proto-oncogene expression in human breast cancer cells. J. Biol. Chem., 263: 9565-9568, 1988.
17. Yang, X., Ferguson, A. T., Nass, S. J., Phillips, D. L., Butash, K. A., Wang, S. M., Herman, J. G., and Davidson, N. E. Transcriptional activation of estrogen receptor α in human breast cancer cells by histone deacetylase inhibition. Cancer Res., 60: 6890-6894, 2000. (Pubitemid 32059160)
18. Kurokawa, H., Lenferink, A. E. G., Simpson, J. F., Pisacane, P. I., Sliwkowski, M. X., Forbes, J. T., and Arteaga, C. L. Inhibition of HER2/neu (erbB2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res., 60: 5887-5894, 2000.
19. Park, J. W., Kirpotin, D. B., Hong, K., Shalaby, R., Shao, Y., Nielsen, U. B., Marks, J. D., Papahadjopoulos, D., and Benz, C. C. Tumor targeting using anti-HER2 immunoliposomes. J. Controlled Release, 74: 95-113, 2001. (Pubitemid 32727613)
20. Smith, C. L., and Hager, G. L. Transcriptional regulation of mammalian genes in vivo: a tale of two templates. J. Biol. Chem., 272: 27493-27496, 1997. (Pubitemid 27473531)
21. Wilusz, C. J., Wormington, M., and Peltz, S. W. The cap-to-tail guide to mRNA turnover. Nat. Rev. Mol. Cell Biol., 2: 237-246, 2001. (Pubitemid 33676966)
22. Marks, P. A., Richon, V. M., and Rifkind, R. A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst., 92: 1210-1216, 2000. (Pubitemid 30627729)
23. Weidle, U. H., and Grossmann, A. Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment. Anticancer Res., 20: 1471-1485, 2000. (Pubitemid 30628153)
24. Yoshida, M., Kijima, M., Akita, M., and Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem., 265: 17171-17179, 1990.
25. Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., and Pavletich, N. P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature (Lond.), 401: 188-193, 1999. (Pubitemid 29436325)
26. Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., and Nakanishi, O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA, 96: 4592-4597, 1999. (Pubitemid 29190381)
27. Vigushin, D. M., Ali, S., Pace, P. E., Mirsaidi, N., Ito, K., Adcock, I., and Coombes, R. C. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin. Cancer Res., 7: 971-976, 2001. (Pubitemid 32708736)
28. Munster, P. N., Troso-Sandoval, T., Rosen, N., Rifkind, R., Marks, P. A., and Richon, V. M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res., 61: 8492-8497, 2001. (Pubitemid 33131130)
29. Sterner, D. E., and Berger, S. L. Acetylation of histones and transcrip-ion-related factors. Microbiol. Mol. Biol. Rev., 64: 435-459, 2000.
30. Yao, Y-L., Yang, W-M., and Seto, E. Regulation of transcription factor YYI by acetylation and deacetylation. Mol. Cell. Biol., 21: 5979-5991, 2001. (Pubitemid 32737814)
31. Van Lint, C., Emiliani, S., and Verdin, E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr., 5: 245-253, 1996.
32. Mariadason, J. M., Corner, G. A., and Augenlicht, L. H. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res., 60: 4561-4572, 2001. (Pubitemid 32103641)
33. Scott, G. K., Marden, C., Andrews, D., Kirk, L., Neve, R. M., and Benz, C. C. A genomically integrated ErbB2 promoter-reporting cell system for high-throughput screening and detection of compounds with potential ErbB2 promoter silencing activity. Proceedings of the 2001 AACR-NCI-EORTC International Conference. Clin. Cancer Res., 7 (Suppl.): 150, 2001.